Abstract
This case report describes a rare instance of cerebral toxoplasmosis in a 37-year-old female following an allogeneic hematopoietic stem cell transplant (HSCT) in South Korea. Despite initial prophylaxis with pentamidine, the patient developed neurological symptoms on day 57 post-transplant. Diagnosis was achieved non-invasively using a serum polymerase chain reaction (PCR) assay after a brain biopsy proved unfeasible due to the location of the lesions and the patient's clinical status. Targeted antimicrobial therapy led to complete clinical and radiological recovery, highlighting the critical importance of specific prophylaxis and molecular diagnostics in immunocompromised populations.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is a primary treatment for various hematologic malignancies and bone marrow failure syndromes. However, the requisite immunosuppression to prevent graft-versus-host disease (GVHD) leaves patients highly susceptible to opportunistic infections. Toxoplasma gondii, a protozoan parasite that persists latently in a significant portion of the global population, can reactivate in these patients, frequently manifesting as life-threatening central nervous system (CNS) disease. In regions like Korea, where the seroprevalence is lower than in Europe or the Americas, clinical data on post-HSCT toxoplasmosis remains scarce, often leading to diagnostic delays.
Case Presentation
A 37-year-old woman presented with neurological deficits 57 days after undergoing HSCT for severe aplastic anemia. Magnetic resonance imaging (MRI) revealed focal lesions in the right caudate nucleus and thalamus. Given the patient's low platelet count and the critical location of the lesions, a stereotactic brain biopsy was attempted but proved unsuccessful.
To confirm the diagnosis, an "in-house" specific PCR assay was performed on the patient's serum. The assay successfully detected T. gondii DNA (206 bp band), providing a definitive diagnosis of cerebral toxoplasmosis without the risks associated with invasive surgical procedures. Serology for IgG and IgM was also conducted, though such tests can be unreliable in the setting of profound immunosuppression.
Results and Clinical Course
Upon diagnosis, the patient was transitioned from broad-spectrum antibiotics to a targeted regimen of pyrimethamine and sulfadiazine. Follow-up PCR testing ten days later was negative, indicating a rapid molecular response to therapy and demonstrating the utility of PCR for monitoring treatment efficacy.
Repeat MRI scans 50 days into treatment demonstrated nearly complete resolution of the previously identified brain lesions. The patient continued maintenance therapy with trimethoprim-sulfamethoxazole (TMP-SMX) for 12 months and remained asymptomatic at her one-year follow-up, representing a full recovery from a condition that carries a mortality rate of approximately 47% in this population.
Discussion
This case underscores several critical clinical points. First, the "prophylaxis gap" was evident; the patient was receiving pentamidine nebulizers for Pneumocystis jirovecii prevention, which offers no protection against Toxoplasma. For seropositive HSCT recipients, TMP-SMX is the preferred prophylactic agent as it covers both pathogens.
Second, the patient’s history of ocular toxoplasmosis a decade prior suggests that the CNS infection was a reactivation of a latent infection, likely triggered by intensified immunosuppression for GVHD. Finally, the utility of serum PCR as a diagnostic tool is paramount when traditional biopsies are contraindicated or fail to yield results.
Conclusion
Clinicians should prioritize pre-transplant screening for Toxoplasma antibodies in both donors and recipients. In seropositive patients, the use of TMP-SMX prophylaxis is essential to prevent devastating neurological complications. This case demonstrates that with early molecular diagnosis and targeted therapy, excellent clinical outcomes are achievable even in high-risk transplant recipients.
Summary updated